7:31 AM ET
8-K
Business Update
Arbutus Biopharma Business Update
Arbutus Biopharma announced that the FDA has lifted the clinical hold on the Investigational New Drug (IND) application for AB-101, its oral PD-L1 inhibitor. The company is now authorized to resume clinical development of the candidate in the United States and is evaluating next steps for its continued development. AB-101 is being developed as a potential treatment for chronic hepatitis B virus (cHBV) infection.